ChromaDex R&D facility earns ISO accreditation for ingredient testing

ISO/IEC 17025:2017 accreditation covers testing of the company's Tru Niagen consumer products, its Niagen ingredient, and phytochemical reference standards

ChromaDex has achieved ISO/IEC 17025:2017 quality standard for laboratory testing, the world's most respected quality management standard.

This accreditation covers testing of the company's Tru Niagen consumer products, its Niagen ingredient, and phytochemical reference standards performed out of its quality control and R&D facility in Longmont, Colorado.

The accreditation requires demonstration of full and continuous compliance with the most rigorous ISO quality standards, enabling ChromaDex to test and analyse its Tru Niagen product, ingredients, and reference standards.

The ISO 17025 accreditation validates the technical proficiency of the state-of-the-art ChromaDex laboratory and its proven ability to consistently generate highly accurate, scientifically defensible product quality data that is traceable to and compliant with international standards.

"This latest accreditation recognizes ChromaDex's consistency in meeting the highest international standards in quality control," ChromaDex CEO Rob Fried said. "Our global partners such as Nestlé have learned to expect these designations along with world-class clinical data."

Dr Andrew Shao, ChromaDex Senior VP of Global Scientific & Regulatory Affairs, added: "The quality and reliability of our products is affirmed through this process. This accreditation helps provide health regulators with confidence in the quality and science behind our products in markets across the globe."

Niagen is tested under ChromaDex's ISO/IEC 17025:2017 accreditation and is the only commercially available nicotinamide riboside (NR) which has twice been successfully reviewed under US Food & Drug Association's (FDA) new dietary ingredient (NDI) notification requirement and successfully notified to the FDA as generally recognised as safe (GRAS).

ChromaDex has also secured regulatory approval on its patent-protected Niagen ingredient in Canada, Australia, and the European Union.

Companies